AGENIX LIMITED
11 Durbell Street
Acacia Ridge QLD 4110
Australia
www.agenix.com

ASX MEDIA RELEASE

7 October, 2008

Agenix Undertakes Capital Raising

Agenix Limited (ASX: AGX) is pleased to advise that it has resolved to raise $800,000, comprising $600,000 through the issue of unlisted convertible notes and a further $200,000 through a private placement of shares.

The proceeds of the Placement will provide funding towards the Phase II ThromboView trial in the USA and steps the company is taking in China to assert its rights over the businesses purchased last year SHRG and YSY.

The placement introduces to the share registry Mr Tang Wen Sen, who has invested $200,000. Mr Tang will take an active part in seeking to resolve the company's difficulties in China. An Appendix 3B and copy of Mr Tang's CV are attached to this announcement.

Under the proposed note issue, the Company will raise up to $600,000. Interest will be payable on the principal of the notes at the rate of 12% per annum on maturity or conversion.

Subject to shareholder approval, the principal of the notes and the accrued interest will automatically convert into shares at the conversion price of 2 cents per share. Shareholder approval for the conversion will be sought at the company's AGM. If shareholder approval is not obtained, the principal and interest must be repaid in full on 1 October 2009.

Jeffrey Luckins
Company Secretary
END

SOURCE: Agenix Limited, Brisbane, Australia
CONTACT: Dr Stephen Phua - Chief Executive Officer
Ph: +65 68465152 or email sphua@agenix.com

Mr. Tang Wen Sen

Mr. Tang is currently a private equity investor in property development, hospital, X-knife Medical Center in China.

Mr. Tang is a limited partner of China Citic Capital Vanka China property fund and serves as an investment consultant to provide strategic advice to the management of property projects in nine cities in China. The fund comprises partners of Vanka, the largest property developer in China, Citic Group in China and GE from the US.

Mr. Tang is a director of Shanghai Yixian Hospital since 1996, a director of Kunming X-knife Medical Center since 1995, and non-executive director of a Shanghai Computer Company developing a hospital MIS package.

Mr. Tang started his business career in 1979 in China marketing, distributing, and installing thousands of Computer systems all over China. During these 30 years of business activities, he organized numerous training seminars and business forums including Chinese drug between Hong Kong, USA and Japan entrepreneurs and many leading institutes in China.

Mr. Tang, who received his degree from University of Manchester in UK, is a member of British Computer Society.

Before he started his own business, he was a lecturer of Hong Kong Polytechnic University and was preparing and marketing software packages as a system consultant in a Hong Kong leading software house.

Mr. Tang was appointed by the Shanghai government as a member of the Chinese People's Political Consultative Conference in 1993. His main interests are secondary school education in China and advising students to study abroad in the US secondary schools and universities, and health care in urban areas of China.

Mr. Tang is married with two sons.

Rule 2.7, 3.10.3, 3.10.4, 3.10.5

Appendix 3B

New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 1/7/96. Origin: Appendix 5. Amended 1/7/98, 1/9/99, 1/7/2000, 30/9/2001, 11/3/2002, 1/1/2003, 24/10/2005.

Name of entity

AGENIX LIMITED

ABN

58 009 213 754

We (the entity) give ASX the following information.

Part 1 - All issues

You must complete the relevant sections (attach sheets if there is not enough space).

1	+Class of +securities issued or to be issued	Fully paid ordinary shares
2	Number of +securities issued or to be issued (if known) or maximum number which may be issued	10,000,000
3	Principal terms of the +securities (eg, if options, exercise price and expiry date; if partly paid +securities, the amount outstanding and due dates for payment; if +convertible securities, the conversion price and dates for conversion)	Fully paid ordinary shares

+ See chapter 19 for defined terms.

4	Do the +securities rank equally in all respects from the date of allotment with an existing +class of quoted +securities? If the additional securities do not rank equally, please state: • the date from which they do • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment	Rank equally with all other ordinary shares
5	Issue price or consideration	$0.02 per share
6	Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets)	Placement
7	Dates of entering +securities into uncertificated holdings or despatch of certificates	5 October 2008

		Number	+Class
8	Number and +class of all +securities quoted on ASX (*including* the securities in clause 2 if applicable)	435,828,711	Fully paid ordinary shares
		20,373,488	Listed options

+ See chapter 19 for defined terms.

		Number	+Class
9	Number and +class of all +securities not quoted on ASX (*including* the securities in clause 2 if applicable)	3,000,000	Non-Listed SHRG Completion Options Expiry Date 17/04/2013 Exercise Price $0.30
		3,000,000	Non-Listed SHRG Completion Options Expiry Date 17/04/2013 Exercise Price $0.40
		3,000,000	Non-Listed SHRG Completion Options Expiry Date 17/04/2013 Exercise Price $0.50
		3,000,000	Non-Listed SHRG Completion Options Expiry Date 17/04/2013 Exercise Price $0.60
		3,000,000	Non-Listed SHRG Completion Options Expiry Date 17/04/2013 Exercise Price $0.70
		326,250	Non-Listed Employee Options Expiry Date 25/07/08 Exercise Price $0.3328
		513,750	Non-Listed Employee Options Expiry Date 21/07/09 Exercise Price $0.4128
		250,000	Options Expiry Date 22/09/09 Exercise Price $0.3928
		534,500	Non-Listed Employee Options Expiry Date 21/07/10 Exercise Price $0.6728
		1,065,750	Non-Listed Employee Options Expiry Date 21/07/11 Exercise Price $0.2928
		200,000	Options Expiry Date 01/01/12 Exercise Price $0.4000

+ See chapter 19 for defined terms.

+ See chapter 19 for defined terms. Appendix 3B Page 4	1,140,000	Non-Listed Employee Options Expiry Date 21/07/12 Exercise Price $0.22
	24,635,250	Total

10	Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)	

Part 2 - Bonus issue or pro rata issue

11	Is security holder approval required?	
12	Is the issue renounceable or non-renounceable?	
13	Ratio in which the +securities will be offered	
14	+Class of +securities to which the offer relates	
15	+Record date to determine entitlements	
16	Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?	
17	Policy for deciding entitlements in relation to fractions	
18	Names of countries in which the entity has +security holders who will not be sent new issue documents Note Security holders must be told how their entitlements are to be dealt with. Cross reference: rule 7.7.	
19	Closing date for receipt of acceptances or renunciations	

20	Names of any underwriters	
21	Amount of any underwriting fee or commission	
22	Names of any brokers to the issue	
23	Fee or commission payable to the broker to the issue	
24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of +security holders	
25	If the issue is contingent on +security holders' approval, the date of the meeting	
26	Date entitlement and acceptance form and prospectus or Product Disclosure Statement will be sent to persons entitled	
27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders	
28	Date rights trading will begin (if applicable)	
29	Date rights trading will end (if applicable)	
30	How do +security holders sell their entitlements *in full* through a broker?	
31	How do +security holders sell *part* of their entitlements through a broker and accept for the balance?	

+ See chapter 19 for defined terms.

32	How do +security holders dispose of their entitlements (except by sale through a broker)?	
33	+Despatch date	

Part 3 - Quotation of securities

You need only complete this section if you are applying for quotation of securities

34 Type of securities
(*tick one*)

(a) ☒ Securities described in Part 1

(b) ☐ All other securities

Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities

Entities that have ticked box 34(a)

Additional securities forming a new class of securities

Tick to indicate you are providing the information or documents

35 ☐ If the +securities are +equity securities, the names of the 20 largest holders of the additional +securities, and the number and percentage of additional +securities held by those holders

36 ☐ If the +securities are +equity securities, a distribution schedule of the additional +securities setting out the number of holders in the categories
1 - 1,000
1,001 - 5,000
5,001 - 10,000
10,001 - 100,000
100,001 and over

37 ☐ A copy of any trust deed for the additional +securities

+ See chapter 19 for defined terms.

Entities that have ticked box 34(b)

38 Number of securities for which +quotation is sought

39 Class of +securities for which quotation is sought

40 Do the +securities rank equally in all respects from the date of allotment with an existing +class of quoted +securities?

If the additional securities do not rank equally, please state:
- the date from which they do
- the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment
- the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment

41 Reason for request for quotation now

Example: In the case of restricted securities, end of restriction period

(if issued upon conversion of another security, clearly identify that other security)

42 Number and +class of all +securities quoted on ASX (*including* the securities in clause 38)

Number	+Class

+ See chapter 19 for defined terms.

Quotation agreement

1 +Quotation of our additional +securities is in ASX's absolute discretion. ASX may quote the +securities on any conditions it decides.

2 We warrant the following to ASX.

- The issue of the +securities to be quoted complies with the law and is not for an illegal purpose.

- There is no reason why those +securities should not be granted +quotation.

- An offer of the +securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

  Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any +securities to be quoted and that no-one has any right to return any +securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the +securities be quoted.

- If we are a trust, we warrant that no person has the right to return the +securities to be quoted under section 1019B of the Corporations Act at the time that we request that the +securities be quoted.

3 We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.

4 We give ASX the information and documents required by this form. If any information or document not available now, will give it to ASX before +quotation of the +securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here: .... Date: 6 October 2008
(Company Secretary)

Print name: Jeffrey Luckins

== == == == ==